Exscientia vs Predible Health

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Exscientia employs 100-500 people, while Predible Health has 10-50 employees.

Exscientia has raised more in total funding at $500M, compared to Predible Health's $5M — a gap of $495M.

Exscientia holds the higher Awaira Score at 72/100, compared to Predible Health's 50/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 22-point gap that reflects meaningful differences in scale or traction.

Exscientia was founded by Andrew Hopkins in 2012. Predible Health was founded by Sanjoy Paul in 2017. Visit each company's profile on Awaira for a full founder biography.

Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners. Predible Health: Predible Health develops AI software for radiology and medical imaging analysis, with a focus on automated CT scan interpretation for lung nodule detection, COVID-19 assessment, and liver segmentation. The platform integrates with radiology information systems and PACS to provide AI-assisted second reads and quantitative measurements that reduce reporting time and flag critical findings for urgent review.\n\nThe company raised approximately $5M in Series A funding and has established clinical partnerships with hospital networks and diagnostic imaging centers across India. Predible Health received significant validation through its COVID-19 CT analysis tool, which was deployed during the pandemic to help overwhelmed radiology departments manage surge volumes.\n\nRadiology AI represents one of the most commercially mature segments of medical AI globally, with clear clinical workflows, measurable radiologist productivity benefits, and established reimbursement pathways emerging in developed markets. Predible Health's India-focused deployments position it as a domestic alternative to global radiology AI companies, with the advantage of deep integration knowledge in Indian hospital IT environments.

Exscientia was founded first in 2012, giving it 5 years of additional market experience. Predible Health was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Exscientia has approximately 100-500 employees, while Predible Health has approximately 10-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Exscientia and Predible Health are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.